Reuters logo
Alexion drug misses goal in late-stage trial
2016年6月6日 / 晚上8点52分 / 1 年前

Alexion drug misses goal in late-stage trial

June 6 (Reuters) - Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial, sending its shares down 9 percent in extended trade.

The drug is being studied as a potential treatment for refractory generalized myasthenia gravis, a debilitating neuromuscular disease.

Soliris is already approved for the rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Shares of Alexion closed $154.99 on Monday on Nasdaq. (Reporting by Shailesh Kuber; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below